High-performance liquid protein therapeutics

APPLICATION OF SIZE EXCLUSION-HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY FOR BIOPHARMACEUTICAL PROTEIN AND PEPTIDE THERAPEUTICS... 

Other therapeutic proteins produced in plants include leuenkephalin, a neuropeptide produced in B. napus and Arabidopsis as part of the seed storage protein 2S albumin. The peptide was proteolytically cleaved from the storage protein and recovered by high-performance liquid chromatography (HPLC). In addition, a biologically active form of the human... 

Liquid chromatography coupled to electrospray ionization mass spectrometry (LC-ESI-MS) was introduced in the 1980s [1]. Today it has become a standard method for separation and characterization of nonvolatile compounds. Reversed-phase high-performance liquid chromatography (RP-HPLC) coupled to ESI-MS is the method of choice for peptide and protein analysis, but also used for the characterization of contaminants, therapeutic drugs, and food additives [2-5], More than 75% of HPLC analyses are run on RP stationary phases, and a wide range of columns are available with various substituents of the silica matrix, base deactivation, endcapping, and column dimensions. 

Immunoadsorption, an advanced therapeutic modality, focuses on detoxification of patient blood rich in high-molecular-weight pathogenic substances, mostly abnormal autoantibodies such as rheumatoid factors in rheumatoid arthritis (RA) and anti-DNA autoantibodies in systemic lupus erythematosus (SLE). Detoxification of these pathogens will be accomplished through extracorporeal perfusion of the patient plasma or whole blood over an affinity column made of immunoadsorbents. These adsorbents perform their function through the same mechanism as conventional affinity adsorption, where proteins in the liquid phase are adsorbed on the specific ligands immobilized onto an insoluble support. 

---